Lithium and GSK-3β inhibitors are commonly used to pharmacologically activate Wnt/β-catenin signaling in preclinical AKI models, but it should be noted about their β-catenin-independent effects (Bao et al., 2014). This evidence concerns the gene GSK3B and acute kidney injury.